Thank you, Mr. Chair.
Thank you to the witnesses for your petitions today.
I have a question for the Lung Association. You talked about the most vulnerable populations, concentrating on the effects on people we know to be at risk. In your presentation, I also heard a certain sense of urgency. How content have you been with the process so far, in terms of the government's ability to mitigate the harm to the most vulnerable populations, when it comes to these substances we're talking about?